May 08, 2018 - Cytosorbents Corp (NASDAQ:CTSO) has filed a financial statement reporting Revenue From Grants of $491,355 USD. Previously, on November 09, 2017, Cytosorbents Corp reported Revenue From Grants of $375,638 USD. This represents a change of 30.81% in Revenue From Grants.

Period EndPeriodValue
2018-03-31 2018-Q1 491,355
2017-09-30 2017-Q3 375,638
2017-06-30 2017-Q2 525,214
2017-03-31 2017-Q1 517,385
2016-09-30 2016-Q3 268,592
2016-06-30 2016-Q2 369,668
2016-03-31 2016-Q1 212,733
2015-09-30 2015-Q3 272,166
2015-06-30 2015-Q2 179,657
2015-03-31 2015-Q1 18,583
2014-09-30 2014-Q3 128,087
2014-06-30 2014-Q2 358,922
2014-03-31 2014-Q1 491,262
2013-09-30 2013-Q3 677,131
2013-06-30 2013-Q2 163,514
2013-03-31 2013-Q1 195,232
2012-09-30 2012-Q3 591,667
2012-06-30 2012-Q2 50,000
2012-03-31 2012-Q1 33,333
2011-09-30 2011-Q3 0

Other Interesting Charts

Accrued Expenses And Other Current Liabilities - Advertising Expense - Allocated Share Based Compensation Expense - Deferred Tax Assets Tax Deferred Expense Reserves And Accruals - Finite Lived Intangible Assets Amortization Expense Next Twelve Months - Finite Lived Intangible Assets Amortization Expense Year Five - Finite Lived Intangible Assets Amortization Expense Year Four - Finite Lived Intangible Assets Amortization Expense Year Three - Finite Lived Intangible Assets Amortization Expense Year Two - Foreign Income Tax Expense Benefit Continuing Operations - Income Tax Expense Benefit - Increase Decrease In Deferred Revenue - Increase Decrease In Prepaid Deferred Expense And Other Assets - Interest Income Expense Nonoperating Net - Lease And Rental Expense - Nonoperating Income Expense - Operating Expenses - Other Sales Revenue Net - Prepaid Expense And Other Assets Current - Research And Development Expense - Revenue From Grants - Sales Revenue Goods Net - Sales Revenue Net - Selling General And Administrative Expense - State And Local Income Tax Expense Benefit Continuing Operations -

Related News Stories

Cytosorbents Stock Could Score Big With Its Blood-Filtering Technology

2018-08-30 investorplace
Cytosorbents (NASDAQ:CTSO) is something of a hit in Europe but is virtually unknown in the U.S. (1-0)

Revisiting Cytosorbents

2018-08-12 seekingalpha
The stock of this name has almost tripled in the past year as investors have bid up this 'razor & razor blade' story. (1-0)

Cytosorbents' (CTSO) CEO Phillip Chan on Q2 2018 Results - Earnings Call Transcript

2018-08-04 seekingalpha
Good afternoon, and welcome to the Cytosorbents Second Quarter 2018 Financial and Operating Results Conference Call. [Operator Instructions] Please be advised that the call will be recorded at the company’s request. (1-2)

Cytosorbents' (CTSO) CEO Phillip Chan on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Good afternoon and welcome to the Cytosorbents' First Quarter 2018 financial and operating results conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded at the Company's request.

CUSIP: 23283X206